Cargando…

A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17

Plaque psoriasis is an immune-mediated inflammatory skin disease associated with the dysregulation of cytokines, especially those involved in the interleukin (IL)-23/IL-17 pathways. In recent years, there has been growing interest in developing biologic therapies that target these pathways. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, April W., Blauvelt, Andrew, Mrowietz, Ulrich, Strober, Bruce, Gisondi, Paolo, Merola, Joseph F., Langley, Richard G., Ståhle, Mona, Lebwohl, Mark, Netea, Mihai G., Nunez Gomez, Natalie, Warren, Richard B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Practical Approach
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941045/ https://www.ncbi.nlm.nih.gov/pubmed/35167107 http://dx.doi.org/10.1007/s13555-022-00687-0

Ejemplares similares

A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm
por: Strober, Bruce, et al.
Publicado: (2021)

A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
por: Armstrong, April W., et al.
Publicado: (2016)

Risk of respiratory infection in patients with plaque psoriasis
por: Svedbom, Axel, et al.
Publicado: (2021)

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies
por: Blauvelt, A., et al.
Publicado: (2020)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
por: Warren, R. B., et al.
Publicado: (2021)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Candida and Host Determinants of Susceptibility to Invasive Candidiasis
por: Lionakis, Michail S., et al.
Publicado: (2013)

Central Pain Sensitization in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2023)

Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks
por: Gisondi, Paolo, et al.
Publicado: (2020)

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015)

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
por: Papp, Kim A., et al.
Publicado: (2021)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
por: Gordon, Kenneth B., et al.
Publicado: (2022)

Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy
por: Davidson, Linda, et al.
Publicado: (2018)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2020)

Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
por: Bellinato, Francesco, et al.
Publicado: (2021)

Recurrent Vulvovaginal Candidiasis: An Immunological Perspective
por: Rosati, Diletta, et al.
Publicado: (2020)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2018)

438 “How do you define Resilience?” Examining the Psychological Resilience of Black Adults Living with Sickle Cell Disease (SCD)
por: Conn, Corinne April Iolanda, et al.
Publicado: (2022)

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
por: Armstrong, April, et al.
Publicado: (2022)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Increased red blood cell distribution width in patients with plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2021)

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
por: Wu, J.J., et al.
Publicado: (2022)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2021)

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
por: Van Voorhees, A.S., et al.
Publicado: (2021)

Interleukin-17 and - 23 Inhibitors Associated with Direct Effects on Depressive Symptoms in Psoriasis: A Register Study
por: SVEDBOM, Axel, et al.
Publicado: (2023)

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2023)

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
por: Gisondi, Paolo, et al.
Publicado: (2020)

Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis
por: Gottlieb, Alice B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g6rbnms8i7i7juhk8ercge5jkb